Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in progressive fibrosing interstitial lung disease
2015-003360-37Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in progressive pulmonary fibrosis (PPF) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Annual rate of decline in forced vital capacity. Started Nov 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on 2015-003360-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003360-37.